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Abstract
Background In a recent study, autoantibodies neutralizing type I interferons (IFNs) were present in at least 10% of cases of
critical COVID-19 pneumonia. These autoantibodies neutralized most type I IFNs but rarely IFN-beta.
Objectives We aimed to define the prevalence of autoantibodies neutralizing type I IFN in a cohort of patients with severe
COVID-19 pneumonia treated with IFN-beta-1b during hospitalization and to analyze their impact on various clinical variables
and outcomes.
Methods We analyzed stored serum/plasma samples and clinical data of COVID-19 patients treated subcutaneously with IFN-
beta-1b from March to May 2020, at the Infanta Leonor University Hospital in Madrid, Spain.
Results The cohort comprised 47 COVID-19 patients with severe pneumonia, 16 of whom (34%) had a critical progression
requiring ICU admission. The median age was 71 years, with 28 men (58.6%). Type I IFN-alpha- and omega-neutralizing
autoantibodies were found in 5 of 47 patients with severe pneumonia or critical disease (10.6%), while they were not found in any
of the 118 asymptomatic controls (p = 0.0016). The autoantibodies did not neutralize IFN-beta. No demographic, comorbidity, or
clinical differences were seen between individuals with or without autoantibodies.We found a significant correlation between the
presence of neutralizing autoantibodies and higher C-reactive protein levels (p = 5.10e−03) and lower lymphocyte counts (p =
1.80e−02). No significant association with response to IFN-beta-1b therapy (p = 0.34) was found. Survival analysis suggested that
neutralizing autoantibodies may increase the risk of death (4/5, 80% vs 12/42, 28.5%).
Conclusion Autoantibodies neutralizing type I IFN underlie severe/critical COVID-19 stages in at least 10% of cases, correlate
with increased C-RP and lower lymphocyte counts, and confer a trend towards increased risk of death. Subcutaneous IFN-beta
treatment of hospitalized patients did not seem to improve clinical outcome. Studies of earlier, ambulatory IFN-beta treatment are
warranted.
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Introduction
In December 2019, infection with severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) emerged in the city
of Wuhan, China. One year later, as of December 22, 2020, it
has caused over 79 million reported cases and at least 1.7
million deaths globally [1]. A striking feature is the vast inter-
individual clinical variability in the course of infection. The
vast majority of infected individuals remain asymptomatic or
develop mild, self-healing, ambulatory disease of the upper
respiratory tract. In approximately 3% of subjects, SARS-
CoV-2 infection results in pneumonia, which in approximate-
ly 0.3% of subjects evolves into acute respiratory distress syn-
drome (ARDS) with systemic inflammation [2]. The identifi-
cation of the determinants of COVID-19 severe pneumonia
could change the current treatment and prognosis of the
disease.
The contribution of inborn errors of immunity to the deter-
minism of severe infectious diseases is well established, par-
ticularly for viral infections, such as severe influenza pneumo-
nia [3, 4]. Autoimmune phenocopies of inborn errors of cyto-
kines, with neutralizing autoantibodies to cytokines, are also
well known [5]. In this context, two studies of the COVID
Human Genetic Effort consortium have recently reported that
in a cohort of nearly 1000 patients with life-threatening
COVID-19 pneumonia, at least 10% showed neutralizing au-
toantibodies against type I interferons (IFNs) [6], while anoth-
er 3.5% carried rare deleterious variants in 8 genes governing
TLR3- and IRF7-dependent type I IFN immunity to influenza
virus [7]. These data provided evidence that defective type I
IFN immunity could underlie life-threatening COVID-19
pneumonia in a significant proportion of cases [8].
The 17 individual type I IFNs are part of both intrinsic and
innate immunity. They are known to increase cell defenses in
response to various viruses, blocking viral spread [9].
Insufficient type I IFN immunity during the first days of in-
fection with SARS-CoV-2 may result in viral spread to the
lungs and via the bloodstream. This spread may in turn
unleash excessive inflammation, including a cytokine
storm, when leukocytes are recruited to infected tissues.
Defects in type I IFN immunity may therefore explain
why some infected subjects develop a severe pneumo-
nia, and progress to an acute respiratory distress syn-
drome (ARDS), systemic inflammation, and critical dis-
ease, requiring admission to the intensive care unit
(ICU). Importantly, autoantibodies to type I IFN neutral-
ize most but not all individual IFNs. They typically
neutralize the 13 IFN-alpha proteins and a single IFN-
omega but rarely neutralize IFN-beta, IFN-kappa, and
IFN-epsilon [6].
The detailed epidemiological and clinical characteristics of
patients with autoantibodies to type I IFNs, as well as their
response to type I IFN therapy, have not been reported. We set
out to study patients from a single hospital in Madrid, Spain,
one of the global epicenters of COVID-19 during the first
wave. We analyzed the presence of autoantibodies against
type I IFNs and compared patients with severe pneumonia
with and without these autoantibodies, in terms of clinical
features and outcome, as well as responses to subcutaneous
IFN-beta therapy during hospitalization. Indeed, in the context
of emerging SARS-CoV2 infection, IFN-beta was adminis-
tered to severe hospitalized patients in the first months of the
pandemic, alone or combined with other drugs, due to the
unavailability of a specific treatment, and their unspecific an-
tiviral effects [9]. Interferons, mainly IFN-beta, have shown to
have in vitro activity against SARS-CoV and MERS-CoV
[10, 11] and to reduce the mortality rate and need for intensive
respiratory support in hospitalized patients [12].
Our sample consisted of 47 hospitalized clinically severe
COVID-19 patients with pneumonia and oxygen support who
were treated subcutaneously with IFN-beta-1b from March to
May 2020. We tested for the presence of autoantibodies
against IFN, and analyzed the possible impact of these auto-
antibodies in different clinical variables and the response to
IFN-beta, in terms of bad prognosis or mortality.
Materials and Methods
We studied data from hospitalized adult patients with
COVID-19 pneumonia treated subcutaneously with recombi-
nant IFN-beta-1b (Betaferon) during admission at the Infanta
Leonor University Hospital in Madrid, Spain, from the first
wave of the pandemic (March toMay 2020), in a retrospective
manner. Based on the local treatment protocol at that time,
when no drug had yet been proven efficacious, IFN-beta-1b
was administered only to patients with severe respiratory fail-
ure and lack of initial response to the standard treatment
(lopinavir/ritonavir, hydroxychloroquine, azithromycin).
We initially selected, from a cohort of 1549 COVID-19
patients admitted to the hospital [13], 47 clinically severe pa-
tients who were treated with IFN-beta-1b (250 μg every 48 h
for up to 14 days) and who had an available plasma sample
collected prospectively during hospitalization and stored in
the hospital sample collection; this criterion was mandatory
to guarantee the possibility to perform a test to determine the
presence of anti-IFN autoantibodies.
All 47 patients were considered clinically severe at admis-
sion following the US National Institutes of Health (NIH)
classification [14]. The patients presented SpO2 < 94% on
room air at sea level, a ratio of arterial partial pressure of
oxygen to fraction of inspired oxygen (PaO2/FiO2)
<300 mmHg, respiratory frequency > 30 breaths/min, or lung
infiltrates >50%. Patients who progressed to an ARDS were
defined as critical following the NIH guidelines [14], with
200 mmHg <PaO2/FiO2 ≤ 300 mmHg to PaO2/FiO2 ≤
J Clin Immunol
100 mmHg, and required support with invasive or noninva-
sive mechanical ventilation at the ICU.
The primary outcome of this retrospective analysis of the
IFN-beta-treated cohort was to evaluate the presence of anti-
IFN autoantibodies. The secondary outcome was the effect of
the presence of these antibodies on different clinical and lab-
oratory variables and disease course.
Clinical data included demographics (age, sex, and ances-
try), comorbidities (arterial hypertension, diabetes, dyslipid-
emia, overweight-obesity, and cardiac, renal, immunological,
or tumor diseases), symptoms (fever and cough), analytics (D-
dimer, C-reactive-protein, ferritin, and lymphocyte counts),
treatment needs (corticosteroids, tocilizumab, and response
to IFN-beta), oxygen needs (nasal cannula and mask or me-
chanical ventilation), and clinical outcomes (days of hospital-
ization, critical stage, and total deaths). The response to IFN-
beta-1b was evaluated as a clinical improvement in no more
than the median 9 days of hospitalization and no need for
escalation in treatment after IFN-beta treatment [13].
The clinical data were collected retrospectively from the
electronic medical records and entered into an anonymous
electronic database (REDCap, Research Electronic Data
Capture) [15]. Different classes of variables were used for this
study: (a) response variables (presence of antibodies: dichot-
omous variable (presence/absence) and antibody titer: quali-
tative variable, factor); (b) explanatory variables: (survival:
measured as time to death or discharge from hospital (cen-
sored data), requirements of O2, the severity of the disease,
positive response to IFN (qualitative variables), and lack of
response to IFN) (assumed with no clinical improvement and
the need for escalation in treatment with a bolus of corticoste-
roids or tocilizumab according to the local protocol or more
than the mean 10 days of hospitalization after interferon ad-
ministration); and (c) covariates: different demographic vari-
ables: comorbidities, laboratory values, symptoms, and
treatments.
The biological blood samples were processed for the deter-
mination of anti-IFN autoantibodies (IFN-alpha, IFN-beta,
and IFN-omega) as described by P. Bastard et al. (2020) [6].
In brief, 96-well ELISA plates (MaxiSorp; Thermo Fisher
Scientific) were coated by incubation overnight at 4 °C with
2 μg/ml rhIFN-α2 (Invitrogen), rhIFN-ω (Merck), or rh-
IFN-β (Invitrogen). Plates were then washed (PBS/
0.005% Tween), blocked by incubation with 5% nonfat
milk powder in the same buffer, washed again, and
incubated with 1:50 dilutions of plasma from the pa-
tients or controls for 2 h at room temperature (or with
specific mAbs as positive controls). Each sample was
tested once. Plates were thoroughly washed. HRP-
conjugated Fc-specific (Fc, fragment crystallizable re-
gion) IgG fractions from polyclonal goat antiserum
ag a i n s t h uman I gG (No r d i c Immuno l o g i c a l
Laboratories) were added to a final concentration of
2 μg/ml. Plates were incubated for 1 h at room temper-
ature and washed. Substrate was added, and the OD
was measured.
Luciferase Reporter Assays The blocking activity of anti-
IFN-α and anti-IFN-ω autoantibodies was determined by
assessing a reporter luciferase activity. Briefly, HEK293T
cells were transfected with the firefly luciferase plasmids un-
der the control human ISRE promoters in the pGL4.45 back-
bone, and a constitutively expressing Renilla luciferase plas-
mid for normalization (pRL-SV40). Cells were transfected in
the presence of the X-tremeGene 9 transfection reagent
(Sigma-Aldrich) for 36 h. The, Dulbecco’s modified Eagle
medium (DMEM, Thermo Fisher Scientific) medium supple-
mented with 10% healthy control or patient serum/plasma and
were either left unstimulated or were stimulated with IFN-α,
IFN-ω, or IFN-β (10 ng/mL) for 16 h at 37 °C. Each sample
was tested once. Finally, Luciferase levels were measured
with the Dual-Glo reagent, according to the manufacturer’s
protocol (Promega). Firefly luciferase values were normalized
against Renilla luciferase values, and fold induction is shown
relative to controls transfected with empty plasmids.
Statistical analysis was carried out using IBM SPSS
Statistics 26.0 (IBM Corp., Armonk, New York, USA). The
variables that did not follow a normal distribution were
expressed using the median and interquartile range (IQR).
Nominal variables were expressed as numbers and percent-
ages. Different models were used to study the association
among the two response variables and the explanatory vari-
ables, as well as the covariates. To analyze the effect of di-
chotomous variables, the Chi2 test was used with a Markov
chain correction for small sample sizes. The nonparametric
Kruskal-Wallis test was used to explore the effect of continu-
ous variables on the presence of antibodies. Likewise, the
nonparametric Kaplan-Meier estimator was used to
univariably analyze the survival function. Survival models
with covariates were tested using the Cox proportional haz-
ards model and the additive model of Aalen.
Informed consent was obtained orally when clinically pos-
sible. In the remaining cases, the informed consent waiver was
authorized by the ethics committee. The study was approved
by the Committee for Ethical Research of the Infanta Leonor
University Hospital, code 008-20, and the Bellvitge
University Hospital code PR127/20.
Results
A total of 47 adult patients with severe COVID-19 and with a
positive nasopharyngeal swab PCR test for SARS-CoV-2
who were treated with IFN-beta-1b (Betaferon) were included
in the study and assayed for the presence of neutralizing au-
toantibodies against type I IFN in plasma, as described by
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Bastard P et al. [6], (Fig. 1). Descriptive demographic and
clinical variables of the included patients are shown in
Table 1. In our cohort, the mean age was 66 years old, the
median age was 71 years old (IQR: 57–75), male sex repre-
sented 59.6% (28) of the study population, the ancestry of
91.4% (43) of the patients was European (41/43 Spaniards),
and only 6.3% (3) were Latin Americans. Preexisting comor-
bidities, as described before, were registered in 93.6% of pa-
tients (44/47). At admission to the hospital, all patients (47/47)
were clinically classified as severe COVID-19 after the NIH
Table 1 Summary of the variables used in this analysis and their
statistical association. The different variables were defined according to
their nature. Continuous variables are shown with the median and
interquartile range [median (IQR)]. Dichotomous variables are
presented with the number of events, the number of total samples and
% [no. events/N (%)]. Additionally, we show the p values of the
association tests (Chi2 test for dichotomous variables, used with a
Markov chain correction for small sample sizes and nonparametric
Kruskal-Wallis test for continuous variables) of the different variables
with the presence/absence of neutralizing autoantibodies
IFN-beta-1b treated cohort No antibodies Neutralizing antibodies p values
Demographics
N 47 42 5
Age (years) 71 (18) 71 (18.5) 64 (17) 0.113
Sex (male) 28/47 (59.6) 25/42 (59.5) 3/5 (60.0) 0.854
Comorbidities
Arterial hypertension 29/47 (61.7) 25/42 (59.5) 4/5 (80.0) 0.669
Diabetes 9/47 (19.1) 9/42 (21.4) 0/5 (0.0) 0.885
Dyslipidemia 18/47 (38.3) 15/42 (35.7) 3/5 (60.0) 0.636
Overweight (BMI >25) 36/39 (92.3) 32/35 (91.4) 4/4 (100) 0.744
Obesity (BMI >30) 21/39 (83) 18/35 (51.4) 3/4 (75.0) 0.601
Renal disease 3/29 (6.4) 2/25 (8.0) 1/4 (25.0) 0.368
Heart disease 8/29 (17.0) 6/25 (24.0) 2/4 (50.0) 0.542
Autoimmune disease 11/47 (23.4) 10/42 (23.8) 1/5 (20.0) 0.874
Tumor disease 14/47 (29.8) 11/35 (31.4) 2/5 (40.0) 0.634
Symptoms at admission
Days with symptoms 5 (4.7) 7 (6) 5 (2) 0.117
Fever 46/47 (97.9) 41/42 (97.6) 5/5 (100) 0.887
Cough 46/47 (97.9) 41/42 (97.6) 5/5 (100) 0.887
Analytics
C-RP maximum (mg/L) 226.3 (172.7) 212.5 (168.1) 360 (63.6) 5.10e−03
Ferritin maximum (ng/ml) 1024 (1.118) 791 (1192.5) 1324 (577) 0.315
D-Dimer maximum (μg/L) 3610 (13,292) 2565 (8850) 191,910 (31,070) 0.144
Lymphocyte count minimum (10E3/μL) 0.5 (0.4) 0.6 (0.3) 0.3 (0) 1.80e−02
Treatments needs
Corticosteroids* 28/47 (59.6) 23/42 (54.7) 5/5 (100) 0.144
Bolus of corticosteroids** 12/47 (25.5) 10/42 (23.8) 4/5 (80) 0.613
Tocilizumab 17/47 (36.2) 14/42 (33.3) 3/5 (60) 0.327
Response to IFN-beta 11/47 (23.4) 11/42 (26.1) 0/5 (0) 0.340
O2 requirements
Nasal cannula 17/47 (36.2) 17/42 (40.4) 0/5 (0) 1.10e−03
High flow reservoir mask 24/47 (29.8) 12/42 (28.5) 2/5 (40) 0.142
Invasive or non-invasive mechanical ventilation 16/47 (34.0) 13/42 (30.9) 3/5 (60) 0.414
Clinical outcomes
Days of hospitalization 14(11) 14 (10.7) 14 (5) 0.258
Critical stage 16/47 (34) 13/42 (30.9) 3/5 (60) 0.339
Total deaths 16/47 (34) 12/42 (28.5) 4/5 (80) 3.40e−02
BMI body mass index, IFN interferon, O2 oxygen. *Dexamethasone 6 mg or methylprednisolone 40 mg daily, oral or intravenous; **intravenous
250 mg of methylprednisolone
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classification [14], and 34% (16/47) of them had an unfavor-
able course, progressing to critical illness.
We tested all patients for the presence of high titer autoan-
tibodies against IFN-alpha2 and/or IFN-omega. We then test-
ed their neutralizing capacity against 10 ng/ml of the corre-
sponding type I IFNs. The prevalence of neutralizing anti-type
I IFN autoantibodies against IFN-alpha proteins and the single
IFN-omega was 10.6% (5 out of 47 in both types) in our
cohort of IFN-beta-treated patients (Fig. 1), while they were
not found in any of the 118 asymptomatic controls (p =
0,0016, Fisher exact test). This finding includes 2 out of 31
severe patients hospitalized (6.4%), and 3 out of 16 patients
with critical progression to an ARDS (18.7%). No neutraliz-
ing autoantibodies against IFN-beta proteins were detected
(Fig. S1). The median age of the patients with autoantibodies
was 64 years (IQR: 58–75 years), 60% (3/5) were males, and
100% were of Caucasian European descent. The patients that
were autoantibody negative (42/47) included 25men (59.5%),
the median age was 71 years (IQR: 56.7–76 years), 92.8%
(39/42) were European, and 7.9% (3/42) were Latin
Americans.
Our data indicate that most of the patients’ baseline char-
acteristics or status at hospital admission did not show a sta-
tistically significant effect on the presence/absence of neutral-
izing autoantibodies according to the Kruskal-Wallis test. No
demographic differences were seen between the individuals
who generated such anti-IFN autoantibodies and those who
did not.
We also did not find significant differences regarding the
presence of a high proportion of comorbidities, including ar-
terial hypertension, obesity, and heart, immunological, or tu-
mor pathology, among the patients who presented
autoantibodies in general, those who presented neutralizing
autoantibodies and those who did not (Table 1).
In contrast, we found a highly significant correlation be-
tween the presence of autoantibodies neutralizing type I IFNs
and raised levels of C-reactive protein (C-RP), over 300 (mg/
L) (p = 5.10e-03), as well as lower lymphocyte counts, well
below 0.5 10E3/μL (p = 1.80e−02). Figure 2 shows the distri-
bution of different acute phase reactants, lymphocyte counts,
days of symptoms, and days of hospitalization in a graphic
display.
Moreover, a significant correlation was found between the
O2 treatment with nasal cannula (p = 1.10e-03) instead ofmore
aggressive measures, and absence of autoantibodies neutraliz-
ing type I IFNs. Indeed, patients with neutralizing autoanti-
bodies needed higher oxygen requirements during hospitali-
zation (40% vs 28.5%). Furthermore, when analyzing the
treatments received by the patients, we did not find a signifi-
cant association between the presence of neutralizing autoan-
tibodies and the administration of corticosteroids (p = 0.14),
bolus of corticosteroids (p = 0.61), tocilizumab against the IL-
6 receptor (p = 0.32), or even response to IFN-beta-1b therapy
(p = 0.34). These factors have been repeatedly related to the
severity and high rates of mortality [16–18].
During hospitalization, the larger proportion of patients 31/
47 (65.9%) remained at severe stage, whereas critical progres-
sion occurred in 34% of patients (16/47), of whom 18.7%
(3/16) presented neutralizing autoantibodies. The median
age of critical patients was 65 years old (IQR: 14.5 years),
63.5 years old (IQR: 20 years) in the patients with neutralizing
autoantibodies, and 68 years old (IQR: 14.7 years) in patients
without them. Male sex represented 75% (12/16) of critical
patients, and in the autoantibody and non-autoantibody sub-
groups, males accounted for 3/4 and 9/12, respectively.
Fig. 1 Neutralizing autoantibodies against IFN-α2 and/or IFN-ω in pa-
tients with life-threatening COVID-19.Multiplex particle-based assay for
auto-Abs against IFN-α2 and IFN-ω in patients with life-threatening
COVID-19 treated with IFN-beta (N = 47), or asymptomatic or mild
SARS-CoV-2 infection (N = 18), and in healthy controls not infected with
SARS-CoV2 (N = 6)
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The global mortality rate in our cohort was 34% (16/47). It
corresponded to 28.6% (12/42) in the non-autoantibody group
and 80% (4/5) in the patients with neutralizing autoantibodies.
The mortality in critical patients was 75% (12/16) globally,
and 3/3 (100%) and 9/12 (75%) in the autoantibody and non-
autoantibody subgroups, respectively.
Of note, we found a significant association between global
mortality and the presence of neutralizing autoantibodies by
Kruskal Wallis (p = 3.4e−02), Table 1. Furthermore,
using the Cox regression, we found that the presence
of neutralizing autoantibodies increased the hazard/ odds
ratio (3.73) (p = 0.04), and we found also significance in
age related to mortality (p = 0.0291), with hazard ratio
1.05, although Aalen regression was not significant
(Table 2). Because of the limitations of the sample size,
we applied additional statistics to analyze survival. In
Fig. 3, Kaplan-Meier statistics shows a trend pointing
to an effect of neutralizing autoantibodies as a factor
increasing the risk of death from COVID-19, although
failing to show statistical significance (p = 0.11).
Discussion
The prevalence of neutralizing anti-IFN-alpha and anti-IFN-
omega autoantibodies in our cohort of severe IFN-beta-treated
patients was 10.6%, confirming the findings in a larger sample
of a recent publication [6] from the COVID Human Genetic
Effort consortium. Our data show that no demographic differ-
ences were present between the individuals who generated
Fig. 2 Box chart. The distribution
of continuous variables from
Table 1 is presented here, with
significantly different levels of C-
reactive protein and lymphocyte
counts
Table 2 Survival analysis: Cox and Aalen regressions. Cox (risk ratio
model) and Aalen (additive model) regressions were adjusted
Cox model Aalen model
OR P-val Coef. P-val
Neutralizing antibodies 3.73 0.0401 0.04 0.4837
Age 1.05 0.0291 0.001 0.095
Sex 0.64 0.4384 −0.01 0.512
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neutralizing anti-IFN autoantibodies (IFN-alpha, IFN-omega)
and those who did not, in terms of age, sex, and ancestry, but
globally, the median age was over 70 years old, and the pre-
dominant sex was male. We also did not detect differences in
terms of comorbidities. The high presence of comorbidities in
our cohort (93.6% of patients) may likely be explained by the
advanced age of the sample, with a median age over 70 years
in both groups. In published cohorts, male patients and elderly
patients or patients ≥50 years are at higher risk of developing
severe disease, whereas comorbidities and clinical manifesta-
tions could significantly affect the prognosis and severity of
COVID-19 [19, 20].
Importantly, we found a statistically significant association
between the presence of neutralizing autoantibodies against
IFN-alpha and IFN-omega, with higher C-reactive protein
values and lower lymphocyte counts. High C-reactive protein
and ferritin concentrations and low lymphocyte counts have
been repeatedly identified as risk predictors of severity and
mortality [21–23].
Additional findings of this study relate to the lack of dif-
ferences in the response to the various treatments used for
COVID-19, including subcutaneous IFN-beta. One possible
explanation may be that patients arrived to the hospital well
advanced in the course of disease, after 2 weeks of symptoms,
and thus, IFN-beta treatment was given late in the course of
infection, restricted to patients with severe pneumonia. This
aspect raises the possibility of using IFN-beta as an earlier,
ambulatory therapeutic option in patients with anti-IFN auto-
antibodies [8]. Indeed, IFN-beta could improve symptoms,
shorten the duration of viral shedding and thus improve prog-
nosis, as recently reported [24, 25]. In this sense, IFN treat-
ment may be a safe and affordable option to improve treat-
ment, especially in the early ambulatory stages of infection.
Furthermore, the absence of neutralizing autoantibodies
against IFN-beta excludes that a putative interference of such
autoantibodies would have counteracted the treatment with
IFN-beta-1b.
The mortality of patients without autoantibodies was
28.5%, similar to published data on severe or critical patients
during the first months of the pandemic [26]. However, in
patients with neutralizing autoantibodies, mortality signifi-
cantly increased to 80%, much higher than the 33.6% previ-
ously described in a larger cohort (37 deaths out of the 101
autoantibody-positive patients in the Bastard study [6]).
Despite the significantly higher mortality in patients with neu-
tralizing autoantibodies when using the Kruskal-Wallis test or
Cox regression, we could not find a statistically significant
correlation between the presence of autoantibodies and higher
mortality when using Kaplan-Meier, or Aalen regression.
Nevertheless, we detect a trend correlating the presence of
neutralizing anti-IFN autoantibodies with the worst clinical
prognosis, although a higher statistical power would be need-
ed to unequivocally demonstrate this point. This study did not
detect effects on survival related to sex, in contrast to the
published data with male patients at higher risk of poor prog-
nosis [19, 27].
The limitation of this pilot study is the small sample size,
compounded by dealing with unbalanced groups with very
dissimilar patient numbers in the groups with or without au-
toantibodies. However, the similarities we found should be
interpreted as strong evidence that the mechanisms at play in
patients with and without autoantibodies are similar. This
finding could suggest that the patients without neutralizing
autoantibodies who died, could have inborn errors of IFN or
autoantibodies not detected by the method used. Moreover,
our results suggest a trend pointing to the presence of antibod-
ies as a risk marker for a worse clinical prognosis.
In sum, larger cohorts will be necessary to confirm the
relationship of anti-IFN autoantibodies and their real impact
on the prognosis andmortality of COVID-19 patients [28, 29].
Our estimates (R software, utility for estimating population
samples) indicate that a sample of at least 192 patients, 96
patients with and 96 patients without autoantibodies, would
be necessary to ascertain a putative correlation with increased
mortality.
To our knowledge, this is the first study that describes a
significant association between the presence of anti-IFN auto-
antibodies and analytical markers of clinical severity and poor
prognoses, such as higher C-reactive protein and lower lym-
phocyte counts. Moreover, the survival analysis suggests a
trend pointing to the presence of high titers of antibodies as
a risk marker for adverse outcome. Late treatment with
Fig. 3 Survival analysis by Kaplan-Meier. Survival analysis of the
presence/absence of anti-interferon autoantibodies (Ab). The p value of
the Kaplan-Meier estimators is presented. In this figure, although not
significant, a trend of a higher risk of death can be foundwith the presence
of neutralizing autoantibodies
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subcutaneous IFN-beta in hospitalized patients with severe or
critical respiratory condition did not improve the clinical re-
sponse or outcomes, as described previously in clinical trials
[25]. These results suggest that a rapid determination of anti-
IFN autoantibodies at admission would be a very useful tool in
the stratification of patients, to adopt early IFN-beta and/or
early intensification of their treatment to minimize the risks
of adverse outcomes, as described recently in a patient with
incontinentia pigmenti and autoantibodies to type I IFNs [30].
This may be even more pertinent in patients with lower lym-
phocyte counts well below 0.5 10E3/μL and C-RP higher than
300 (mg/L), analytes which show a strong correlation with the
presence of neutralizing autoantibodies. Alternatively, ambu-
latory treatment of all infected subjects >65 years of age with
subcutaneous IFN-beta might be considered, as this short-
term treatment appears to be safe, with side-effects mostly
resolving within 3 days after drug initiation, and no severe
adverse events or related deaths reported [25].
Supplementary Information The online version contains supplementary
material available at https://doi.org/10.1007/s10875-021-01036-0.
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